Cargando…

A Screening of Antineoplastic Drugs for Acute Myeloid Leukemia Reveals Contrasting Immunogenic Effects of Etoposide and Fludarabine

Background: Recent evidence demonstrated that the treatment of acute myeloid leukemia (AML) cells with daunorubicin (DNR) but not cytarabine (Ara-C) results in immunogenic cell death (ICD). In the clinical setting, chemotherapy including anthracyclines and Ara-C remains a gold standard for AML treat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ocadlikova, Darina, Iannarone, Clara, Redavid, Anna Rita, Cavo, Michele, Curti, Antonio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7556041/ https://www.ncbi.nlm.nih.gov/pubmed/32948017 http://dx.doi.org/10.3390/ijms21186802

Ejemplares similares

Chemotherapy-Induced Tumor Cell Death at the Crossroads Between Immunogenicity and Immunotolerance: Focus on Acute Myeloid Leukemia
por: Ocadlikova, Darina, et al.
Publicado: (2019)

P1375: VENETOCLAX MODULATES TIM-3 EXPRESSION ON CD8 T CELLS IN ACUTE MYELOID LEUKEMIA PATIENTS
por: Ocadlikova, Darina, et al.
Publicado: (2023)

The More, The Better: “Do the Right Thing” For Natural Killer Immunotherapy in Acute Myeloid Leukemia
por: Parisi, Sarah, et al.
Publicado: (2017)

Mesenchymal stromal cells from myelodysplastic and acute myeloid leukemia patients display in vitro reduced proliferative potential and similar capacity to support leukemia cell survival
por: Corradi, Giulia, et al.
Publicado: (2018)

PGE(2)-Induced IDO1 Inhibits the Capacity of Fully Mature DCs to Elicit an In Vitro Antileukemic Immune Response
por: Trabanelli, Sara, et al.
Publicado: (2015)

Sunitinib Exerts In Vitro Immunomodulatory Activity on Sarcomas via Dendritic Cells and Synergizes With PD-1 Blockade
por: Ocadlikova, Darina, et al.
Publicado: (2021)

An IDO1-related immune gene signature predicts overall survival in acute myeloid leukemia
por: Ragaini, Simone, et al.
Publicado: (2022)

ATP Release from Chemotherapy-Treated Dying Leukemia Cells Elicits an Immune Suppressive Effect by Increasing Regulatory T Cells and Tolerogenic Dendritic Cells
por: Lecciso, Mariangela, et al.
Publicado: (2017)

Immunosenescence and Immunotherapy in Elderly Acute Myeloid Leukemia Patients: Time for a Biology-Driven Approach
por: Isidori, Alessandro, et al.
Publicado: (2018)

Thiotepa-busulfan-fludarabine compared to busulfan-fludarabine for sibling and unrelated donor transplant in acute myeloid leukemia in first remission
por: Saraceni, Francesco, et al.
Publicado: (2017)

Emerging Bone Marrow Microenvironment-Driven Mechanisms of Drug Resistance in Acute Myeloid Leukemia: Tangle or Chance?
por: Ciciarello, Marilena, et al.
Publicado: (2021)

ABT199/venetoclax potentiates the cytotoxicity of alkylating agents and fludarabine in acute myeloid leukemia cells
por: Valdez, Benigno C., et al.
Publicado: (2022)

Mitoxantrone and Etoposide for the Treatment of Acute Myeloid Leukemia Patients in First Relapse
por: Im, Annie, et al.
Publicado: (2016)

Combination of treosulfan, fludarabine and cytarabine as conditioning in patients with acute myeloid leukemia, myelodysplastic syndrome and myeloproliferative neoplasms
por: O‘Hagan Henderson, Samantha, et al.
Publicado: (2021)

The Yin and Yang of the Bone Marrow Microenvironment: Pros and Cons of Mesenchymal Stromal Cells in Acute Myeloid Leukemia
por: Ciciarello, Marilena, et al.
Publicado: (2019)

Antineoplastic effects of CPPTL via the ROS/JNK pathway in acute myeloid leukemia
por: Gao, Hui-Er, et al.
Publicado: (2017)

Fludarabine in the treatment of chronic lymphocytic leukemia: a review
por: Ricci, Francesca, et al.
Publicado: (2009)

Development of fludarabine formulations in the treatment of chronic lymphocytic leukemia
por: Janssens, Ann, et al.
Publicado: (2009)

Fludarabine-induced bradycardia in a patient with refractory leukemia
por: Chung-Lo, Woei, et al.
Publicado: (2010)

RARG Gene Dysregulation in Acute Myeloid Leukemia
por: Conserva, Maria Rosa, et al.
Publicado: (2019)

T-cell large granular lymphocytic leukemia: treatment experience with fludarabine
por: Costa, Renata Oliveira, et al.
Publicado: (2012)

MicroRNAs involvement in fludarabine refractory chronic lymphocytic leukemia
por: Ferracin, Manuela, et al.
Publicado: (2010)

Fludarabine-treosulfan compared to thiotepa-busulfan-fludarabine or FLAMSA as conditioning regimen for patients with primary refractory or relapsed acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT)
por: Saraceni, Francesco, et al.
Publicado: (2019)

PB1826: CELLULAR AND MOLECULAR CHARACTERIZATION OF THE ANTINEOPLASTIC EFFECTS OF CEPHALOCHROMIN IN MODELS OF ACUTE MYELOID LEUKEMIA
por: Nascimento, Mariane Cristina Do, et al.
Publicado: (2023)

Retrospective Comparison of Fludarabine in Combination With Intermediate-Dose Cytarabine Versus High-Dose Cytarabine As Consolidation Therapies for Acute Myeloid Leukemia
por: Zhang, Wenjun, et al.
Publicado: (2014)

Synergistic cytotoxicity of homoharringtonine and etoposide in acute myeloid leukemia cells involves disrupted antioxidant defense
por: Zhang, Jingjing, et al.
Publicado: (2019)

Single-Cell Sequencing: Ariadne’s Thread in the Maze of Acute Myeloid Leukemia
por: Redavid, Immacolata, et al.
Publicado: (2022)

Cell-based evaluation of changes in coagulation activity induced by antineoplastic drugs for the treatment of acute myeloid leukemia
por: Tsunaka, Misae, et al.
Publicado: (2017)

Fludarabine-resistance associates with ceramide metabolism and leukemia stem cell development in chronic lymphocytic leukemia
por: Huang, Chunfa, et al.
Publicado: (2018)

The tissue inhibitor of metalloproteinases-1 (TIMP-1) promotes survival and migration of acute myeloid leukemia cells through CD63/PI3K/Akt/p21 signaling
por: Forte, Dorian, et al.
Publicado: (2016)

Busulfan and Fludarabine Conditioning Regimen Given at Hematological Nadir of Cytoreduction Fludarabine, Cytarabine, and Idarubicin Chemotherapy in Patients With Refractory Acute Myeloid Leukemia Undergoing Allogeneic Stem Cell Transplantation: A Single Arm Pilot Consort Study
por: Tang, Wei, et al.
Publicado: (2015)

Post-column coulometric generation and cyclic voltammetric identification of the free radical of the antineoplastic agent etoposide (VP 16-213)
por: Ploegmakers, H. H. J. L., et al.
Publicado: (1988)

P558: ABSOLUTE LYMPHOCYTE COUNT IS AN INDEPENDENT SURVIVAL PREDICTOR COMPARED TO MINIMAL RESIDUAL DISEASE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA TREATED WITH INTENSIVE CHEMOTHERAPY
por: Cristiano, Gianluca, et al.
Publicado: (2023)

Renin angiotensin system genes are biomarkers for personalized treatment of acute myeloid leukemia with Doxorubicin as well as etoposide
por: Turk, Seyhan, et al.
Publicado: (2020)

Alemtuzumab in the treatment of fludarabine refractory B-cell chronic lymphocytic leukemia (CLL)
por: Montillo, Marco, et al.
Publicado: (2008)

Fludarabine Treatment of Patient with Chronic Lymphocytic Leukemia Induces a Digital Ischemia
por: Soyaltin, Utku Erdem, et al.
Publicado: (2016)

Overcoming Resistance to Kinase Inhibitors: The Paradigm of Chronic Myeloid Leukemia
por: De Santis, Sara, et al.
Publicado: (2022)

Comparison of fludarabine–melphalan and fludarabine–treosulfan as conditioning prior to allogeneic hematopoietic cell transplantation—a registry study on behalf of the EBMT Acute Leukemia Working Party
por: Duque-Afonso, Jesus, et al.
Publicado: (2022)

P1318: THE IMPACT OF MELPHALAN DOSING IN COMBINATION WITH FLUDARABINE IN CLINICAL OUTCOMES OF PATIENTS WITH ACUTE MYELOID LEUKEMIA AND MYELODYSPLASTIC SYNDROMES RECEIVING ALLO-HCT
por: Albanyan, O., et al.
Publicado: (2022)

Computerized cyclic voltammetric detection after HPLC of the antineoplastic agents etoposide, teniposide, adriamycin and its metabolite adriamycinol in urine samples
por: Ploegmakers, H. H. J. L., et al.
Publicado: (1989)

Cannot write session to /tmp/vufind_sessions/sess_ok0vas4cbfs3ou5fvk1optsn86